P3.02c-088 Acquired Resistance to Programmed Death-1 Axis Inhibitors in Non-Small Cell Lung Cancer (NSCLC) Jungmin Choi, Ryan Sowell, Anna Truini, Kurt.

Slides:

Advertisements

Similar presentations

A2-06: Survival differences for non-Bronchioloalveolar Carcinoma (BAC) non-small-cell lung cancer (NSCLC) cases with ipsilateral intrapulmonary metastasis.

Advertisements

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

SC17.02 Lung Cancer in China: Challenges and Perspectives

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

SC09.04 Radiotherapy in China

MA12.06 Tumor Spread through Air Spaces (STAS) in Lung Squamous Cell Cancer is an Independent Risk Factor: A Competing Risk Analysis Shaohua Lu, Takashi.

NA Journal of Thoracic Oncology

Electronic Updates for JTO Readers

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

P3.02c-030 Use of a 200-Mg Fixed Dose of Pembrolizumab for the Treatment of Advanced Non–Small Cell Lung Cancer (NSCLC) Edward Garon, Martin Reck, Delvys.

P The Effect of Two Interventions on Attainment of Surgical Quality Measures in Resected Non-Small Cell Lung Cancer (NSCLC) Nicholas Faris, Meredith.

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

PUB023 Effectiveness of Three-Dimensional Video System in Single Port Thorascopic Major Pulmonary Resection: Propensity Score Matched Analysis Hyun Koo.

P Risk Stratification Model to Predict Survival Following Surgical Resection for Lung Cancer Using Pathological Variables Timothy Edwards, Charlene.

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green

P Molecular Characterization of Non-Small Cell Lung Cancers (NSCLC) in Young Patients from an Argentine Population V. Denninghoff, G. Recondo,

P SARON: Stereotactic Ablative Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer (NSCLC). A UK Randomized Phase III Trial Yenting Ngai,

P3.02c-026 Is Nivolumab Safe and Effective in Elderly and PS2 Patients with Non-Small Cell Lung Cancer (NSCLC)? Results of CheckMate 153 David Spigel,

MA17.03 Identifying Genomic Alteration and Inter-Tumor Heterogeneity of Multiple Primary Lung Cancers by Targeted NGS of Tumor Tissue and ctDNA Kezhong.

P3.02b-125 Failure to Tyrosine Kinase Inhibitors and Patterns of Progression in Patients with Advanced Non-Small Cell Lung Cancer Feliciano Barron, Laura-Alejandra.

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

P3.02b-075 Addition of Bevacizumab for Malignant Pleural Effusion as the Manifestation of Acquired EGFR-TKI Resistance in NSCLC Patients Tao Jiang, Shengxiang.

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

P3.02b-062 Safety of Necitumumab and Abemaciclib Combination Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Benjamin Besse, Johan.

P Predictors of Survival after Whole Brain Radiotherapy for Patients with Brain Metastasized Lung Cancer Georgios Tsakonas, Fatou Hellman, Signe.

PD5-2-5: Local therapy of primary diseae improves survival in non-small cell lung cancer metastatic to a single organ - a lesson from brain metastases

PS02.17 A Biomarker-Driven Algorithm for Sequencing of Systemic Therapy for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Survey of 25 Investigators

ED11.01 Systemic Therapy for Advanced Oncogene-Driven NSCLC

P3.02b-061 A Phase II Study of Nab-Paclitaxel (Nab-P) in Patients with Advanced Non- Small Cell Lung Cancer (NSCLC) with EGFR Mutations Christina Baik,

Vamsidhar Velcheti, MD Journal of Thoracic Oncology

Heidi B. Rolke, Frode Gallefoss Journal of Thoracic Oncology

P Accuracy of Combined Semantic and Computational CT Features in Predicting Non-Small Cell Lung Cancer Subtype Usman Bashir, Andrea Bille, Levon.

Mitotic Inhibitors Journal of Thoracic Oncology

JCSE01.16 Positive Correlation Between Whole Genomic Copy Number Variant Scoring and the Grading System in Lung Non-Mucinous Invasive Adenocarcinoma

An Unmet Need in the WHO 2015 Biopsy Classification: Poorly Differentiated NSCCs with Positive Neuroendocrine Markers Jules L. Derks, MD Journal of.

ES Lung Cancer Surgery for High Risk Patients

P Circulating Biomarkers of Frailty Are Associated with a Poor Prognosis in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Nicola.

A1-02: A need to standardize post-operative radiotherapy (PORT) fields used for non- small cell lung cancer (NSCLC): analysis of an international dummy-run.

MTP13-01: Indications and limitations of bronchoscopy

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

MA Comparison of EORTC, PERCIST, PeterMac & Deauville PET Response Criteria after Radical ChemoRT in Non-Small-Cell Lung Cancer G. Turgeon, A.

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

P3.02b-052 Afatinib with or without Cetuximab for First-Line Treatment of EGFR-Mutant NSCLC: Interim Safety Results of SWOG S1403 Sarah Goldberg, James.

P3.02a-023 Treatment Patterns and Early Outcomes of ALK+ Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study Edmond Bendaly,

A2-06: Survival differences for non-Bronchioloalveolar Carcinoma (BAC) non-small-cell lung cancer (NSCLC) cases with ipsilateral intrapulmonary metastasis.

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non– Small Cell Lung Cancer Emily Castellanos, MD, Emily Feld, MD, Leora.

M. Kusumoto Journal of Thoracic Oncology

OA07.06 In Early-Stage Lung Adenocarcinomas, Survival by Tumor Size (T) is Further Stratified by Tumor Spread through Air Spaces Takashi Eguchi, Koji.

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

MTP19-01: T4 N0/N1 nonsmall cell lung cancer can be cured as a first line treatment with an expected five year survival rate as high as 43% provided a.

European Lung Cancer Conference (ELCC) 2016 Organisation

OA Video-Assisted Thoracoscopic Surgery vs

P2.03b-002 Efficacy and Safety of WBRT Combined with Endostar in Patients with Advanced Non-Small Cell Lung Cancer Xiaorong Dong, Ruiguang Zhang, Xican.

PS01.07 The Clinical Necessity of Extended Thymectomy for Thymic Squamous Cell Carcinomas Revealed by Exome Sequencing J. Jiang, Y. Zhang, C. Jin, J.

3A.01 Efficacy of Programmatic Combined Stereotactic Ablative Radiotherapy and Anti- PD-1 Therapy in Advanced Lung Cancer: A Retrospective Analysis A.

IASLC 6th Latin American Conference on Lung Cancer

PS01.37: Comparison Between Sanger Sequencing and ARMS qPCR Method for EGFR Gene Mutation Detection of Non–Small Cell Lung Cancer Jiexia Zhang, Xiaoshun.

P Post-Recurrence Survival Analysis of Stage I Non-Small Cell Lung Cancer: Prognostic Significance of Local Treatment Kanghoon Lee, Hyeong Ryul.

OA Survival Trends Among Non-Small Cell Lung Cancer (NSCLC) Patients Over A Decade: Impact of Initial Therapy at Academic Centers B. Dholaria,

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

M. Pasquinelli, Z. Deliu, D. Rosenberg, C. Weldon, S. Obilade, A

Journal of Thoracic Oncology

P1. 02: Lung Cancer - A Previously Years Survival Study

A Review of First-Line Treatment for Small-cell Lung Cancer

Mark A. Socinski, MD Journal of Thoracic Oncology

MA01.03 The Non-Invasive LuCED® Test for Detection of Early Stage Lung Cancer Michael Meyer, Timothy Bell, Daniel Sussman, David Wilbur, Chris Presley,

Robert Comis, MD, The Passing of a “Lung Man”

ED04.01 Surgery in Bronchopulmonary Typical and Atypical Carcinoids

Presentation transcript:

P3.02c-088 Acquired Resistance to Programmed Death-1 Axis Inhibitors in Non-Small Cell Lung Cancer (NSCLC) Jungmin Choi, Ryan Sowell, Anna Truini, Kurt Schalper, Anna Wurtz, Guoping Cai, Curtis Perry, Ila Datar, Katherine Hastings, Mary Ann Melnick, Edward Kaftan, Paula Kavathas, Susan Kaech, David Rimm, Sarah Goldberg, Anne Chiang, Richard Lifton, Lieping Chen, Roy Herbst, Katerina Politi, Scott Gettinger Journal of Thoracic Oncology Volume 12, Issue 1, Pages S1331-S1332 (January 2017) DOI: 10.1016/j.jtho.2016.11.1884 Copyright © 2016 Terms and Conditions

Journal of Thoracic Oncology 2017 12, S1331-S1332DOI: (10.1016/j.jtho.2016.11.1884) Copyright © 2016 Terms and Conditions